Leczenie tlenoterapią hiperbaryczną (HBOT) jako opcja terapeutyczna dla chorych na atopowe zapalenie skóry (AZS) – doświadczenia własne i przegląd piśmiennictwa

Olszański, R.; Konarski, M.; Siermontowski, P.

doi:10.1515/phr-2017-00012

Artykuł - szczegóły

Tytuł artykułu

Leczenie tlenoterapią hiperbaryczną (HBOT) jako opcja terapeutyczna dla chorych na atopowe zapalenie skóry (AZS) – doświadczenia własne i przegląd piśmiennictwa

Autorzy

Olszański R. , Konarski M. , Siermontowski P.

Treść / Zawartość

Pełne teksty:

Pobierz

Pobierz

Identyfikatory

DOI

10.1515/phr-2017-00012

Warianty tytułu

Hyperbaric oxygen therapy (HBOT) as a therapeutic option for patients with atopic dermatitis (AD) – OWN experiences and literature review

Języki publikacji

PL EN

Abstrakty

W pracy przedstawiono wyniki leczenia dziesięciu pacjentow chorujących na ciężką postać atopowego zapalenia skory (AZS), nie reagujących na typową farmakoterapię, ktorych poddano leczeniu tlenoterapią hiperbaryczną (HBOT). U każdego z pacjentow zastosowano 10 ekspozycji tlenowych przy pO2 2,5 ATA (~250 kPa) i czasie trwania 60 min. Na czas realizacji procedur hiperbarycznych u wszystkich chorych odstawiono leczenie ogolne, utrzymując typowe postępowanie miejscowe. W grupie badanej przeprowadzano oceną kliniczną, a także określano poziom immunoglobulin: IgA, IgG, IgM i IgE oraz składowych C3 i C4 dopełniacza. U wszystkich pacjentow uzyskano poprawę kliniczną, a także stwierdzono zmniejszenie się poziomu immunoglobuliny IgE i składowej dopełniacza C3 po zakończeniu cyklu ekspozycji. Biorąc pod uwagę obserwacje własne i dane z piśmiennictwa, ogolna poprawa stanu klinicznego oraz obniżenie poziomu immunoglobuliny E i składowej C3 dopełniacza po cyklu ekspozycji może świadczyć o immunomodulującym wpływie HBOT na przebieg AZS, a tlenoterapia hiperbaryczna może stanowić opcję terapeutyczną dla niektorych chorych na AZS, w szczegolności tych słabo reagujących na standardowe leczenie.

The paper discusses the treatment results of ten patients with severe atopic dermatitis (AD) who did not respond to standard pharmacotherapy and underwent hyperbaric oxygen therapy (HBOT). Each patient was subject to 10 oxygen exposures at pO2 2.5 ATA (~ 250 kPa) with the duration time of 60 minutes. In the period of implementation of the hyperbaric procedures the general treatment plan was suspended for all patients while maintaining typical local treatment. Clinical evaluation was performed in the study group as well as determination of levels of immunoglobulins: IgA, IgG, IgM and IgE and C3 and C4 complement. All patients indicated clinical improvement and a decreased IgE immunoglobulin and complement C3 level upon the completion of the exposure cycle. Taking into account the authors' own observations and data from literature, an overall improvement in the clinical status and a decrease in the level of immunoglobulin E and C3 complement following a cycle of exposures may be indicative of an immunomodulating HBOT effect on AD, whereas hyperbaric oxygenation may constitute a therapeutic option for some patients with AD, especially those exhibiting a poor response to standard treatment.

Słowa kluczowe

atopowe zapalenie skóry HBOT immunoglobuliny IgE układ dopełniacza immunomodulacja

atopic dermatitis HBOT immunoglobulins IgE complement immunomodulation

Wydawca

Polskie Towarzystwo Medycyny i Techniki Hiperbarycznej

Czasopismo

Polish Hyperbaric Research

Rocznik

2017

Tom

nr 3(60)

Strony

27--36

Opis fizyczny

Bibliogr. 66 poz., tab.

Twórcy

autor

Olszański R.

romuald.olszanski@wp.pl

Zakład Medycyny Morskiej i Hiperbarycznej, Gdynia, Wojskowego Instytutu Medycznego w Warszawie

autor

Konarski M.

Zakład Technologii Prac Podwodnych Akademii Marynarki Wojennej w Gdyni

autor

Siermontowski P.

Zakład Medycyny Morskiej i Hiperbarycznej, Gdynia, Wojskowego Instytutu Medycznego w Warszawie

Bibliografia

1. Mathieu D, Marroni A, Kot J (2017) Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and nonaccepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med, 47(1): 24-32. PMID: 28357821;
2. Thom SR (2011) Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg, 127 (Suppl 1): 131S-141S. DOI:10.1097/PRS.0b013e3181fbe2bf;
3. Kierznikowicz B, Ulewicz K (1976) Influence of oxygen hyperbaria on the activity of complement in human’s sera. Acta Physiol Pol, 27: 409-411. PMID: 983722;
4. Hansbrough JF, Piacentine JG, Eiseman B (1980) Immunosuppression by hyperbaric oxygen. Surgery, 87: 662-667. PMID: 7376077;
5. Ulewicz K, Zannini D (1986) On the possibility of hyperbaric oxygen therapy in some pathological reactions of immunological hypersensitivity. Bull Inst Mar Trop Med Gdynia, 37 (1-2): 71-79. PMID: 3555661;
6. Saito K, Tanaka Y, Ota T, Eto S, Yamashita U (1991) Suppressive effect of hyperbaric oxygenation on immune responses of normal and autoimmune mice. Clin Exp Immunol, 86: 322-327. DOI: 10.1111/j.1365-2249.1991.tb05817.x;
7. Olszański R, Pachut M, Sićko Z, Sztaba-Kania M, Wilkowska A (1992) Efficacy of hyperbaric oxygenation in atopic dermatitis. Bull Inst Mar Trop Med Gdynia, 43 (1-4): 79-82. PMID: 1345603;
8. Di Cesare A, Di Meglio P, Nestle FO (2008) A role for Th17 cells in the immunopathogenesis of atopic dermatitis ? J Invest Dermatol, 128: 2569-2571. DOI: 10.1038/jid.2008.283;
9. Kudchodkar BJ, Jones H, Simecka J, Dory L (2008) Hyperbaric oxygen treatment attenuates the pro-inflammatory and immune responses in apolipoprotein E knockout mice. Clin Immunol, 128(3): 435-441. DOI:10.1016/j.clim.2008.05.004;
10. Hultqvist M, Olsson LM, Gelderman KA, Holmdahl R (2009) The protective role of ROS in autoimmune disease. Trends Immunol, 30: 201-208. DOI:10.1016/j.it.2009.03.004;
11. Kim HR, Kim JH, Choi EJ, Lee YK, Kie JH, Jang MH, Seoh JY (2014) Hyperoxygenation attenuated a murine model of Atopic Dermatitis through raising skin level of ROS. PLoS ONE, 9 (10): e109297. DOI: 10.1371/journal.pone.0109297;
12. Berke R, Singh A, Guralnick M (2012) Atopic dermatitis: an overview. Am Fam Physician, 86: 35-42. PMID: 22962911;
13. Nowicki R, Trzeciak M, Wilkowska A, Sokołowska-Wojdyło M, Ługowska-Umer H, Barańska-Rybak W, Kaczmarski M, Kowalewski C, Kruszewski J, Maj J, Silny W, Śpiewak R, Petranyuk A (2015) Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. Postep Derm Alergol, 32 (4): 239-249. DOI: 10.5114/pdia.2015.53319;
14. Won HY, Sohn JH, Min HJ, Lee K, Woo HA, Ho YS, Park JW, Rhee SG, Hwang ES (2010) Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing Th2 and Th17 cell development. Antioxid Redox Signal, 13: 575-587. DOI: 10.1089/ars.2009.2989;
15. Erdmann D, Roth AC, Hussmann J, Lyons SF, Mody NJ, Kucan JO, Russell RC (1995) Skin allograft rejection and hyperbaric oxygen treatment in immune-histoincompatible mice. Undersea Hyperb Med 22: 395-399. PMID: 8574127;
16. Kudchodkar BJ, Wilson J, Lacko A, Dory L (2000) Hyperbaric oxygen reduces the progression and accelerates the regression of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol, 20: 1637-1643. DOI: 10.1161/01.ATV.20.6.1637;
17. Akin ML, Gulluoglu BM, Uluutku H, Erenoglu C, Elbuken E, Yildirim S, Celenk T (2002) Hyperbaric oxygen improves healing in experimental rat colitis. Undersea Hyperb Med, 29: 279-285. PMID: 12797669;
18. Benson RM, Minter LM, Osborne BA (2003) Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human bloodderived monocyte-macrophages. Clin Exp Immunol, 134: 57-62. DOI: 10.1046/j.1365-2249.2003.02248.x;
19. Butler G, Michaels JC, Al-Waili N, Finkelstein M, Allen M, Petrillo R, Carrey Z, Kolanuvada B, Lee BY, Riera AG, Michaels CC, Urteaga G (2009) Therapeutic effect of hyperbaric oxygen in psoriasis vulgaris: two case reports and a review of the literature. J Med Case Rep, 3: 7023. DOI: 10.4076/1752-1947-3-7023
20. Olivieri AN, Mellos A, Duilio C, Di Meglio M, Mauro A, Perrone L (2010) Refractory vasculitic ulcer of the toe in adolescent suffering from Systemic Lupus Erythematosus treated successfully with hyperbaric oxygen therapy. Ital J Pediatr, 36: 72. DOI:10.1186/1824-7288-36-72;
21. Faleo G, Fotino C, Bocca N, Molano RD, Zahr-Akrawi E, Molina J, Villate S, Umland O, Skyler JS, Bayer AL, Ricordi C, Pileggi A (2012) Prevention of autoimmune diabetes and induction of beta-cell proliferation in NOD mice by hyperbaric oxygen therapy. Diabetes, 61: 1769-1778. DOI: 10.2337/db11-0516;
22. Jacob BB, Thuning CA, Sacksteder MR, Warren JM (1979) Extended skin allograft survival in mice during prolonged exposure to hyperbaric oxygen. Transplantation 28: 70-72. PMID: 377598;
23. Granowitz EV, Skulsky EJ, Benson RM, Wright J, Garb JL, Cohen ER, Smithline EC, Brown RB (2002) Exposure to increased pressure or hyperbaric oxygen suppresses interferon-gamma secretion in whole blood cultures of healthy humans. Undersea Hyperb Med, 29: 216-225. PMID: 12670123;
24. Nie H, Xiong L, Lao N, Chen S, Xu N, Zhu Z (2006) Hyperbaric oxygen preconditioning induces tolerance against spinal cord ischemia by upregulation of antioxidant enzymes in rabbits. J Cereb Blood Flow Metab, 26: 666-674. DOI: 10.1038/sj.jcbfm.9600221;
25. Zhang J, Fife CE, Currie MS, Moon RE, Piantadosi CA, Vann RD (1991) Venous gas emboli and complement activation after deep repetitive air diving. Undersea Biomed Res, 18 (4): 293-302. PMID: 1887517;
26. Pekna M, Ersson A (1996) Complement system response to decompression. Undersea Hyperb Med, 23 (1): 31-34. PMID: 8653063;
27. Konarski M, Olszański R, Baj Z, Buczyński A, Kłos R, Skrzyński S (2000) [Influence of air hyperbaric exposures on selected haematological parameters and complement system] [Article in Polish]. Pol Przegl Med Lot, 6 (1): 25-31. ISSN 1233-0779;
28. Olszański R, Konarski M, Kierznikowicz B (2002) Changes of selected morphotic parameters and blood plasma proteins in blood of divers after a single short-time operational heliox exposure. Int Marit Health, 53 (1-4): 111-121. PMID: 12608594;
29. Kłos R, Konarski M, Olszański R (2004) The implementation of factor analysis for the evaluation of selected blood parameter changes induced by hyperbaric exposure. Int Marit Health, 55 (1-4): 87-102. PMID: 15881546;
30. Nyquist P, Ball R, Sheridan MJ (2007) Complement levels before and after dives with a high risk of DCS. Undersea Hyperb Med, 34 (3): 191-197. PMID: 17672175;
31. Warren J, Sacksteder MR, Thuning CA (1978) Oxygen immunosuppression: modification of experimental allergic encephalomyelitis in rodents. J Immunol, 121 (1): 315-320. PMID: 670704;
32. Bokeriia LA, Frolova MA, Kostava VT (1979) [Suppression of humoral antibody synthesis on exposure to hyperbaric oxygenation] [Article in Russian, English abstract]. Biull Eksp Biol Med, 87 (4): 320-322. PMID: 571294;
33. Bean JW, Smith CW (1952) Hypophyseal and adrenocortical factors in pulmonary damage induced by oxygen at atmospheric pressure. Am J Physiol, 172: 169-174. PMID: 13030734;
34. Houlihan RT, WeinerRE, Zavodni J (1966) Adrenocortical response to stimulated high altitude and to oxygen at high pressures. Physiologist, 9: 206 [abstract];
35. Brenner I, Shephard RJ, Shek PN (1999) Immune function in hyperbaric environments, diving, and decompression. Undersea Hyperb Med, 26 27-39. PMID: 10353182;
36. Garthwaite J (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci, 14: 60-67. DOI: 10.1016/0166-2236(91)90022-M;
37. Bredt DS, Snyder SH (1992) Nitric oxide, a novel neuronal messenger. Neuron, 8: 3-11. DOI: 10.1016/0896-6273(92)90104-L;
38. Inamoto Y, Okuno F, Saito K, Tanaka Y, Watanabe K, Morimoto I, Yamashita U, Eto S (1991) Effect of hyperbaric oxygenation on macrophage function in mice. Biochem Biophys Res Commun, 179: 886-891. DOI: 10.1016/0006-291X(91)91901-N;
39. Mialon P, Barthelemy L (1993) Effect of hyperbaric oxygen on prostaglandin and thromboxane synthesis in the cortex and the striatum of rat brain. Mol Chem Neuropathol, 20: 181-189. DOI: 10.1007/BF02815371;
40. Yang ZJ, Bosco G, Montante A, Ou XI, Camporesi EM (2001) Hyperbaric O2 reduces intestinal ischemia-reperfusion-induced TNF-alpha production and lung neutrophil sequestration. Eur J Appl Physiol 85: 96-103. DOI: 10.1007/s004210100503;
41. Şen H, Erbağ G, Ovali MA, Öztopuz RÖ, Uzun M (2016) Investigation of endocrine and immunological response in fat tissue to hyperbaric oxygen administration in rats. Cell Mol Biol (Noisy-le-grand), 62 (5): 15-19. PMID: 27188864
42. Yin W, Badr AE, Mychaskiw G, Zhang JH (2002) Down regulation of COX-2 is involved in hyperbaric oxygen treatment in a rat transient focal cerebral ischemia model. Brain Res, 926: 165-171. DOI: 10.1016/S0006-8993(01)03304-2;
43. de Vries JE (1995) Immunosuppressive and anti-inflammatory properties of IL-10. Ann Med, 27: 537-541. DOI: 10.3109/07853899509002465;
44. Marx RE, Ehler WJ, Tayapongsak P, Pierce LW (1990) Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg, 160: 519-524. DOI: 10.1016/S0002-9610(05)81019-0;
45. Luongo C, Imperatore F, Cuzzocrea S, Filippelli A, Scafuro MA, Mangoni G, Portolano F, Rossi F (1998) Effects of hyperbaric oxygen exposure on a zymosan-induced shock model. Crit Care Med, 26: 1972-1976. DOI: 10.1097/00003246-199812000-00022;
46. Xu X, Yi H, Kato M, Suzuki H, Kobayashi S, Takahashi H, Nakashima I (1997) Differential sensitivities to hyperbaric oxygen of lymphocyte subpopulations of normal and autoimmune mice. Immunol Lett, 59: 79-84. DOI: 10.1016/S0165-2478(97)00104-1;
47. Takeshima F, Makiyama K, Doi T (1999) Hyperbaric oxygen as adjunct therapy for Crohn’s intractable enteric ulcer. Am J Gastroenterol, 94: 3374-3375. DOI: 10.1111/j.1572-0241.1999.03374.x;
48. Buchman AL, Fife C, Torres C, Smith L, Aristizibal J (2001) Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol, 33: 337-339. DOI: 10.1097/00004836-200110000-00018;
49. Freeman BA, Crapo JD (1981) Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem, 256: 10986-10992. PMID: 7287745;
50. Jamieson D, Chance B, Cadenas E, Boveris A (1986) The relation of free radical production to hyperoxia. Annu Rev Physiol, 48: 703-719. DOI: 10.1146/annurev.ph.48.030186.003415;
51. Jamieson D (1991) Lipid peroxidation in brain and lungs from mice exposed to hyperoxia. Biochem Pharmacol, 41: 749-756. DOI: 10.1016/0006-2952(91)90076-H;
52. Dennog C, Radermacher P, Barnett YA, Speita G (1999) Antioxidant status in humans after exposure to hyperbaric oxygen. Mutation Res, 428: 83-89. DOI: 10.1016/S1383-5742(99)00034-4;
53. Thom SR (2009) Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol, 106: 988-995. DOI: 10.1152/japplphysiol.91004.2008;
54. George-Chandy A, Nordström I, Nygren E, Jonsson IM, Postigo J, Collins LV, Eriksson K (2008) Th17 development and autoimmune arthritis in the absence of reactive oxygen species. Eur J Immunol, 38: 1118-1126. DOI: 10.1002/eji.200737348;
55. Kraaij MD, Savage ND, van der Kooij SW, Koekkoek K, Wang J, van den Bergd JM, Ottenhoff THM, Kuijpers TW, Holmdahle R, van Kootena C, Geldermana KA (2010) Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc Natl Acad Sci USA, 107: 17686-17691. DOI:10.1073/pnas.1012016107/-/DCSupplemental;
56. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, Luo W, Zeller K, Shimoda L, Topalian SL, Semenza GL, Dang CV, Pardoll DM, Pan F (2011) Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell, 146: 772-784. DOI: 10.1016/j.cell.2011.07.033;
57. Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol, 34: 137-143. DOI: 10.1016/j.it.2012.10.001;
58. Lee K, Won HY, Bae MA, Hong JH, Hwang ES (2011) Spontaneous and aging-dependent development of arthritis in NADPH oxidase 2 deficiency through altered differentiation of CD11b+ and Th/Treg cells. Proc Natl Acad Sci USA, 108: 9548-9553. DOI: 10.1073/pnas.1012645108;
59. Won HY, Jang EJ, Lee K, Oh S, Kim HK, Woo HA, Kang SW, Yu DY, Rhee SG, Hwang ES (2013) Ablation of peroxiredoxin II attenuates experimental colitis by increasing FoxO1-induced Foxp3+ regulatory T cells. J Immunol, 191: 4029-4037. DOI: 10.4049/jimmunol.1203247;
60. Olszański R, Konarski M, Kłos R, Siermontowski P (1999) [Oxygen exposures and diver's safety] [Article in Polish]. Lek Wojsk, 75 (1-2): 71-77. ISSN: 0024-0745;
61. Kleen M, Messmer K (1999) Toxicity of high PaO2. Minerva Anestesiol, 65: 393-396. PMID: 10394808;
62. Torbati D, Church DF, Keller JM, Pryor WA (1992) Free radical generation in the brain precedes hyperbaric oxygen-induced convulsions. Free Radic Biol Med, 13: 101-106. DOI: 10.1016/0891-5849(92)90070-W;
63. Thom SR, Bhopale V, Fisher D, Manevich Y, Huang PL, Buerk DG (2002) Stimulation of nitric oxide synthase in cerebral cortex due to elevated partial pressures of oxygen: an oxidative stress response. J Neurobiol, 51: 85-100. DOI: 10.1002/neu.10044;
64. Harabin AL, Braisted JC, Flynn ET (1990) Response of antioxidant enzymes to intermittent and continuous hyperbaric oxygen. J Appl Physiol, 69: 328-635. PMID: 2394655;
65. Narkowicz CH, Vial JH, McCartney PW (1993) Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radic Res Commun, 19: 71-80. DOI: 10.3109/10715769309056501;
66. Dennog C, Hartmann A, Frey G, Speit G (1996) Detection of DNA damage after hyperbaric oxygen (HBO) therapy. Mutagenesis, 11: 605-609. DOI: 10.1093/mutage/11.6.605.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-b30973d3-b4ab-4834-bb70-a973c82915ef